Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Inmune Bio (INMB) Receivables - Other (2021 - 2025)

Inmune Bio (INMB) has disclosed Receivables - Other for 5 consecutive years, with $257000.0 as the latest value for Q4 2025.

  • Quarterly Receivables - Other rose 12.72% to $257000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $257000.0 through Dec 2025, up 12.72% year-over-year, with the annual reading at $257000.0 for FY2025, 12.72% up from the prior year.
  • Receivables - Other hit $257000.0 in Q4 2025 for Inmune Bio, down from $760000.0 in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $760000.0 in Q3 2025 to a low of $100000.0 in Q3 2022.
  • Historically, Receivables - Other has averaged $379928.6 across 5 years, with a median of $331000.0 in 2021.
  • Biggest five-year swings in Receivables - Other: surged 48.34% in 2023 and later plummeted 76.12% in 2025.
  • Year by year, Receivables - Other stood at $300000.0 in 2021, then rose by 20.67% to $362000.0 in 2022, then soared by 48.34% to $537000.0 in 2023, then tumbled by 57.54% to $228000.0 in 2024, then grew by 12.72% to $257000.0 in 2025.
  • Business Quant data shows Receivables - Other for INMB at $257000.0 in Q4 2025, $760000.0 in Q3 2025, and $550000.0 in Q2 2025.